Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
128 studies found for:    Immunodeficiency NOT AIDS | Open Studies
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases
Condition: Severe Immunodeficiency Diseases
Intervention: Drug: Fludarabine, Busulfan, and Anti-Thymocyte Globulin
2 Not yet recruiting Novel Testing Procedures
Condition: Immunodeficiencies
Intervention:
3 Not yet recruiting IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
Condition: Primary Immunodeficiency
Intervention: Drug: IgHy10
4 Not yet recruiting Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiencies
Condition: Severe Combined Immunodeficiency
Intervention: Biological: TBX-1400
5 Recruiting Genetic Basis of Immunodeficiency
Condition: Severe Combined Immunodeficiency
Intervention:
6 Not yet recruiting ASIS for GAMMAGARD in Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Drug: Gadolinium For abdomen;   Drug: Gadolinium For lower back;   Drug: Efficacy of Gammagard subcutaneously at Week 12;   Drug: Efficacy of Gammagard subcutaneously at Week 24;   Drug: Efficacy of Gammagard subcutaneously at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 12;   Drug: Efficacy of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 12;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 36;   Drug: Adverse Reactions of Gammagard subdermally at Week 12;   Drug: Adverse Reactions of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subdermally at Week 36
7 Recruiting Generalized Neonatal Screening of Severe Combined Immunodeficiencies
Condition: Severe Combined Immunodeficiency, Atypical
Intervention: Biological: SCID screening
8 Recruiting Intensive Care Unit and Secondary and Primary Immune Deficiency
Condition: Primary Immune Deficiency Disorder
Intervention: Other: Internal Medicine consultation
9 Recruiting Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndromes
Interventions: Procedure: blood sampling and skin biopsy;   Procedure: blood sampling or mouth swap;   Procedure: blood sampling
10 Not yet recruiting Neonatal Screening of Severe Combined Immunodeficiencies
Conditions: Severe Combined Immunodeficiency;   Neonatal Screening
Intervention:
11 Recruiting Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Biological: IGIV-C 10%;   Biological: IGSC 20%
12 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
13 Recruiting Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Condition: Primary Immunodeficiency Disease (PIDD)
Intervention:
14 Recruiting Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Condition: Immunologic Deficiency Syndromes
Intervention: Biological: GC5107
15 Recruiting Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
Condition: Severe Combined Immunodeficiency Disease, X-linked
Interventions: Genetic: CL20-4i-EF/a-hyc-OPT;   Drug: Busulfan
16 Recruiting A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
Condition: Primary Immunodeficiency
Interventions: Device: Chrono Super PID then Generic Syringe-Gammanorm;   Device: Generic Syringe then Chrono Super PID-Gammanorm
17 Recruiting Diagnostic Immunization With Rabies Vaccine in Patients With PID
Condition: Primary Immunodeficiency
Intervention: Biological: Verorab® (PVRV; Purified Vero Cell Vaccine)
18 Recruiting Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
Condition: Primary Immunodeficiency
Intervention: Biological: IGSC 20%
19 Recruiting Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps
Condition: Primary Immunodeficiency (PID)
Intervention: Biological: Gammanorm
20 Recruiting Systematic Search for Primary Immunodeficiency in Adults With Infections
Conditions: Complement Deficiency;   Antibody Deficiency;   Chronic Sinus Infection;   Meningitis, Bacterial;   Pneumonia, Bacterial;   Otitis Media;   Streptococcal Infection;   Neisseria Infections;   Haemophilus Influenza;   Pneumococcal Infections
Intervention: Biological: Immunological diagnosis tests

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.